What does a markedly elevated soluble transferrin receptor in a patient with low hemoglobin/hematocrit and thrombocytosis indicate?

Interpretation of Elevated Soluble Transferrin Receptor with Low Hemoglobin and Thrombocytosis

This laboratory pattern—markedly elevated soluble transferrin receptor (sTfR), low hemoglobin/hematocrit, and thrombocytosis—indicates active iron-deficient erythropoiesis, most commonly from absolute iron deficiency anemia, though it can also reflect functional iron deficiency or increased erythropoietic drive from hemolysis or ineffective erythropoiesis.

Understanding Soluble Transferrin Receptor Physiology

• sTfR is a truncated monomer of the tissue transferrin receptor that circulates in serum, primarily released by erythroid precursors in the bone marrow rather than reticulocytes. 1

• The concentration of sTfR directly reflects total body transferrin receptor expression and marrow erythropoietic activity, varying up to 8-fold below and 20-fold above normal values depending on erythropoietic demand. 1

• sTfR levels rise early in iron deficiency with the onset of iron-deficient erythropoiesis and continue to increase as iron-deficient erythropoiesis progressively worsens, even before anemia develops. 2

• Critically, sTfR is considerably elevated in iron deficiency anemia but remains normal in uncomplicated anemia of chronic disease, making it particularly useful for identifying concomitant iron deficiency in patients with inflammation when ferritin values are falsely elevated. 3, 1

Clinical Significance of Elevated sTfR

Primary Diagnostic Interpretation

• All patients with absent bone marrow iron stores have elevated sTfR levels, making it the most sensitive serum biochemical marker for identifying iron-deficient erythropoiesis. 4

• sTfR levels correlate better than bone marrow iron stores with decreased mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC), confirming its superiority as a functional marker of iron availability for red cell production. 4

• Normal bone marrow iron stores can coexist with elevated sTfR and decreased MCV/MCHC, defining functional iron deficiency where iron is sequestered and unavailable for erythropoiesis despite adequate storage. 4

Differential Diagnosis Based on sTfR Elevation

When sTfR is markedly elevated, consider these diagnostic categories:

1. Absolute iron deficiency anemia: sTfR is considerably elevated, ferritin is low (<30 ng/mL without inflammation or <100 ng/mL with inflammation), and transferrin saturation is <16–20%. 3, 1

2. Functional iron deficiency (anemia of chronic disease with iron restriction): sTfR is elevated, ferritin is 100–300 ng/mL, transferrin saturation is <20%, and inflammatory markers (CRP) are elevated. 5, 1

3. Hemolytic anemias: sTfR is increased due to expanded erythropoiesis compensating for red cell destruction. 2

4. Myelodysplastic syndromes: sTfR is elevated from ineffective erythropoiesis. 2

5. Erythropoietin therapy: sTfR rises with stimulated erythropoiesis. 2

Thrombocytosis as a Diagnostic Clue

• Thrombocytosis peaks in the third week of iron deficiency and serves as a reactive marker; its presence strongly favors iron deficiency over anemia of chronic disease, where platelet elevation is uncommon. 6

• The combination of elevated sTfR with thrombocytosis in the setting of microcytic anemia is highly specific for iron-deficient erythropoiesis rather than other causes of microcytosis such as thalassemia trait or anemia of chronic disease. 6

Diagnostic Algorithm for This Laboratory Pattern

Step 1 – Confirm iron-deficient erythropoiesis:

• Measure serum ferritin, transferrin saturation (TSAT), and C-reactive protein (CRP) to distinguish absolute from functional iron deficiency. 5
• Ferritin <30 ng/mL (no inflammation) or <100 ng/mL (with inflammation) plus TSAT <16–20% confirms absolute iron deficiency. 5
• Ferritin 100–300 ng/mL plus TSAT <20% with elevated CRP defines functional iron deficiency. 5

Step 2 – Investigate the underlying cause:

• In adult men with hemoglobin <110 g/L or non-menstruating women with hemoglobin <100 g/L, urgent bidirectional endoscopy (upper endoscopy with duodenal biopsies plus colonoscopy) is mandatory to exclude gastrointestinal malignancy and other bleeding sources. 6
• Upper endoscopy with duodenal biopsies screens for celiac disease (present in 2–3% of iron deficiency cases), gastric cancer, peptic ulcer disease, and NSAID-induced gastropathy. 6
• Colonoscopy detects colonic carcinoma, adenomatous polyps, angiodysplasia, and inflammatory bowel disease. 6
• In premenopausal women, assess menstrual blood loss patterns and consider gynecologic evaluation. 5

Step 3 – Exclude conditions with increased erythropoiesis:

• If ferritin and TSAT are normal or elevated, consider hemolytic anemia (check reticulocyte count, haptoglobin, LDH, indirect bilirubin) or myelodysplastic syndrome (peripheral smear, bone marrow examination if indicated). 2
• Review medication history for erythropoiesis-stimulating agents, which elevate sTfR independent of iron status. 2

Diagnostic Utility of sTfR in Special Populations

Inflammatory Conditions

• sTfR measurement is particularly valuable to detect concomitant iron deficiency in patients with inflammation because sTfR levels remain mostly normal in functional iron deficiency but are elevated when true tissue iron deficiency coexists with chronic disease. 3

• The finding that sTfR levels remain mostly normal in functional iron deficiency is particularly useful to identify children and adults who require iron replacement strategies in areas with high infection prevalence. 3

• The sTfR/log ferritin ratio is valuable for distinguishing anemia of chronic inflammation from iron deficiency anemia, whether the latter occurs alone or in combination with anemia of chronic inflammation. 2

Pediatric Populations

• A significant proportion of children with reduced ferritin levels have iron-deficient erythropoiesis without anemia, reflected by elevated sTfR levels. 3

• However, sTfR levels may not be increased in iron-deficient infants less than 1 year of age, limiting its diagnostic utility in this specific age group. 3

Treatment Implications

Once iron-deficient erythropoiesis is confirmed by elevated sTfR:

• For absolute iron deficiency without inflammation, initiate oral iron supplementation (ferrous sulfate 200 mg three times daily) and expect hemoglobin to rise ≥10 g/L within 2 weeks. 6

• For functional iron deficiency or malabsorption, intravenous iron (ferric carboxymaltose, iron sucrose, or low-molecular-weight iron dextran) is required because it bypasses hepcidin-mediated intestinal blockade. 5

• In chronic kidney disease or heart failure patients with elevated sTfR and TSAT <20%, IV iron is preferred and should target TSAT ≥20% to ensure adequate iron availability for erythropoiesis. 5

• If erythropoiesis-stimulating agents are used, maintain TSAT >20% during therapy because ESAs require iron supplementation to optimize dose-response and red blood cell production. 5

Critical Pitfalls to Avoid

• Do not assume elevated sTfR always indicates iron deficiency; it also rises with hemolysis, myelodysplastic syndromes, and erythropoietin therapy, requiring correlation with ferritin, TSAT, and clinical context. 2

• Do not rely on ferritin alone when inflammation is present; sTfR provides superior diagnostic accuracy because it is not an acute-phase reactant. 3, 1

• Do not delay investigation of the underlying cause while treating with iron; in adults with confirmed iron deficiency, gastrointestinal evaluation is mandatory to exclude malignancy. 6

• Recognize that as a single investigation, sTfR does not discriminate between absent iron stores and restricted iron supply due to anemia of chronic disease—both elevate sTfR—so ferritin and TSAT must be measured concurrently. 4

• Be aware that different commercial sTfR assays give disparate values due to lack of an international standard, so cutoff points for iron deficiency diagnosis vary by method (ranging from 2.48 to 6.70 mg/L in different assays). 7